Relacorilant
Hypercortisolism (Cushing Syndrome) - GRACE study
Key Facts
About Corcept Therapeutics
Corcept Therapeutics is a leader in cortisol modulation science, with over 25 years of research and the discovery of more than 1,000 proprietary selective cortisol modulators. The company's mission is to unlock the potential of cortisol modulation to revolutionize the treatment of serious diseases, supported by a robust pipeline with more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology. With its first FDA-approved product generating revenue and multiple late-stage clinical programs, Corcept is positioned to expand its impact significantly in the coming years.
View full company profileAbout Corcept Therapeutics
Corcept Therapeutics is a leader in cortisol modulation science, with over 25 years of research and the discovery of more than 1,000 proprietary selective cortisol modulators. The company's mission is to unlock the potential of cortisol modulation to revolutionize the treatment of serious diseases, supported by a robust pipeline with more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology. With its first FDA-approved product generating revenue and multiple late-stage clinical programs, Corcept is positioned to expand its impact significantly in the coming years.
View full company profileAbout Corcept Therapeutics
Corcept Therapeutics is a leader in cortisol modulation science, with over 25 years of research and the discovery of more than 1,000 proprietary selective cortisol modulators. The company's mission is to unlock the potential of cortisol modulation to revolutionize the treatment of serious diseases, supported by a robust pipeline with more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology. With its first FDA-approved product generating revenue and multiple late-stage clinical programs, Corcept is positioned to expand its impact significantly in the coming years.
View full company profile